NeoGenomics (NEO) 2025 Conference June 04, 2025 02:00 PM ET Speaker0 Afternoon. I'm Tycho Peterson from the Life Science Tools Group. It's my pleasure to introduce our next company this afternoon, NeoGenomics. Tony, I'm going to maybe open it up with you. You've had a little bit of time in the CEO role here. Just talk about early learnings, how you're kind of thinking about stepping in, any big changes that need to happen? Speaker1 No. I think it's been a really good introductory period for me. I had the op ...

NeoGenomics (NEO) FY Conference June 03, 2025 01:00 PM ET Speaker0 All right, hi everyone. Good afternoon. Thanks for joining us here. First day of the William Blair Growth Stock Conference. If you don't know me, I'm Andrew Brackman. I'm the diagnostics analyst here at William Blair. On my team, Maggie Bowie and Kate Jansen here in the second row. You see us around the conference, feel free to say hi. We're happy to chat anything and everything diagnostics. With us today we have NeoGenomics. We have the who ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation ...

NeoGenomics (NEO) Q1 2025 Earnings Call April 29, 2025 01:46 PM ET Speaker0 Greetings, and welcome to the NeoGenomics First Quarter twenty twenty five Conference Call. At this time, all participants are on a listen only mode, and a question and answer session will follow the formal presentation. Please note this conference is being recorded. I will now turn the conference over to your host, Kendra Sweeney, VP of Investor Relations. Ma'am, you may begin. Speaker1 Thank you, Ellie. Good morning, everyone, and ...

业绩总结 - 2025年第一季度收入为1.68亿美元，同比增长8%[36] - 调整后的毛利润为7900万美元，同比增长11%[31] - 调整后的EBITDA为700万美元，同比增长102%[31] - 2025年第一季度净亏损为2592.3万美元，较上年减少[47] - 2025年第一季度总收入为168,035千美元，较2024年同期的156,240千美元增长7.5%[51] - 2025年第一季度毛利为73,246千美元，较2024年同期的65,469千美元增长11.9%[51] - 2025年第一季度调整后EBITDA为7,070千美元，较2024年同期的3,492千美元显著增长[53] - 2025年第一季度净损失为25,923千美元，较2024年同期的27,061千美元有所减少[53] 用户数据 - 临床NGS收入增长18%[17] - 临床测试量同比增长8%，达到32.6万单位[31] 未来展望 - 预计2025财年收入指导范围为7.47亿至7.59亿美元，同比增长13%至15%[38] - 2025年预计净损失范围为77,000千美元至85,000千美元[57] 新产品和新技术研发 - Pathline收购预计将增加1200万至1400万美元的收入[38] 现金流和财务状况 - 现金及现金等价物为3.46亿美元，较上年增长4.3%[36] - 2025年第一季度现金及现金等价物期末余额为346,194千美元，较2024年同期的331,914千美元有所增加[49] - 2025年第一季度净现金用于经营活动为25,327千美元，较2024年同期的25,915千美元有所改善[49] - 2025年第一季度投资活动提供的净现金为3,560千美元，较2024年同期的14,525千美元下降[49] 其他信息 - 调整后的毛利率提高至47%，较上年增加146个基点[32] - 2025年第一季度调整后毛利率为46.8%，较2024年同期的45.3%有所提升[51] - 2025年第一季度股权激励费用为10,754千美元，较2024年同期的7,774千美元增加[53]

NeoGenomics (NEO) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 100%. A quarter ago, it was expected that this operator of cancer-focused testing laboratories would post earnings of $0.02 per share when it actually produced earnings of $0.04, delivering a surprise of 100%.Over the last four ...

NeoGenomics (NEO) Q1 2025 Earnings Call April 29, 2025 08:30 AM ET Company Participants Kendra Sweeney - Vice President of Investor Relations & CommunicationsTony Zook - CEOWarren Stone - President & COOAndrew Lukowiak - Chief Innovation OfficerJeffrey Sherman - Chief Financial OfficerDaniel Brennan - Managing DirectorMatthew Sykes - Financial AdvisorKareem Saad - Head of Strategy & TransformationMichael Ryskin - Managing DirectorAndrew Cooper - VP - Equity ResearchJack Melick - Equity Research AssociatePun ...

Fort Myers, Florida (April 29, 2025) - NeoGenomics, Inc. (NASDAQ: NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first-quarter results for the period ended March 31, 2025. Exhibit 99.1 NeoGenomics Reports First Quarter 2025 Results Consolidated Revenue Increased 8% to $168 million First Quarter 2025 Highlights As Compared To First Quarter 2024 "Our business is off to a solid start in 2025 with our team delivering a record number ...

TORONTO, April 25, 2025 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “Company”) (TSXV: NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, as part of the Battery Board Transition Initiative, is highly pleased to announce the appointment of Mr. Kenneth Hoffman, CFA, CIM, to its Board of Directors, effective immediately. Mr. Hoffman is an internationally distinguished expert in battery materials with over 30 years o ...

About SBC Medical SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with ...